Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: A single blind, non-inferiority, randomised controlled trial

The Lancet Oncology

Volumn 14, Issue 7, 2013, Pages 647-654

  Arits, Aimée HMM ^a,b   Mosterd, Klara ^a,b   Essers, Brigitte AB ^a   Spoorenberg, Eefje ^a,c   Sommer, Anja ^a,b,d   De Rooij, Michette JM ^e   van Pelt, Han PA ^e   Quaedvlieg, Patricia JF ^f   Krekels, Gertruud AM ^g   van Neer, Pierre AFA ^h   Rijzewijk, Joris J ⁱ   van Geest, Adrienne J ^j   Steijlen, Peter M ^a,b   Nelemans, Patty J ^a   Kelleners Smeets, Nicole WJ ^a,b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Kolbach Clinic   (Netherlands)

^e VIECURI MEDICAL CENTER   (Netherlands)

^f Sittard Geleen Heerlen   (Netherlands)

^g CATHARINA HOSPITAL   (Netherlands)

^h LAURENTIUS HOSPITAL   (Netherlands)

ⁱ ELKERLIEK HOSPITAL   (Netherlands)

^j JEROEN BOSCH HOSPITAL   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; FLUOROURACIL; IMIQUIMOD;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; BLISTER; BURNING SENSATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EROSION; ERYSIPELAS; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; LEG ULCER; LIGHT EMITTING DIODE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; PAIN; PATIENT COMPLIANCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SKIN SWELLING; SKIN TINGLING; SUPERFICIAL BASAL CELL CARCINOMA; TUMOR RECURRENCE; WOUND INFECTION;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; AMINOQUINOLINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROGNOSIS; SINGLE-BLIND METHOD; SKIN NEOPLASMS;

EID: 84878346748     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70143-8     Document Type: Article

References (28)

1. Lomas A, Leonardi-Bee J, Bath-Hextall F A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012, 166:1069-1080.
2. Flohil SC, de Vries E, Neumann HA, Coebergh JW, Nijsten T Incidence, prevalence and future trends of primary basal cell carcinoma in the Netherlands. Acta Derm Venereol 2011, 91:24-30.
3. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003, 48:425-429.
4. Rippey JJ Why classify basal cell carcinomas?. Histopathology 1998, 32:393-398.
5. Arits AH, Schlangen MH, Nelemans PJ, Kelleners-Smeets NW Trends in the incidence of basal cell carcinoma by histopathological subtype. J Eur Acad Dermatol Venereol 2011, 25:565-569.
6. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007, 56:125-143.
7. Telfer NR, Colver GB, Morton CA Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008, 159:35-48.
8. Raymond L Barnhill MD 1998, Textbook of Dermatopathology: McGraw-Hill Companies.
9. Levine HL, Bailin PL Basal cell carcinoma of the head and neck: identification of the high risk patient. Laryngoscope 1980, 90:955-961.
10. Panje WR, Ceilley RI The influence of embryology of the mid-face on the spread of epithelial malignancies. Laryngoscope 1979, 89:1914-1920.
11. Morton CA Methyl aminolevulinate (Metvix) photodynamic therapy-practical pearls. J Dermatolog Treat 2003, 14:23-26.
12. Schon MP, Schon M Imiquimod: mode of action. Br J Dermatol 2007, 157:8-13.
13. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004, 50:722-733.
14. Breuninger H, Sebastian G, Kortmann RD, Schwipper V, Werner J, Garbe C Brief guidelines: basal cell carcinoma of the skin. J Dtsch Dermatol Ges 2006, 4:441-443.
15. Goette DK Topical chemotherapy with 5-fluorouracil. A review. J Am Acad Dermatol 1981, 4:633-649.
16. Mosterd K, Arits AH, Nelemans PJ, Kelleners-Smeets NW Aesthetic evaluation after non-invasive treatment for superficial basal cell carcinoma. J Eur Acad Dermatol Venereol 2013, 5:647-650.
17. Cosgarea R, Susan M, Crisan M, Senila S Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol 2012, published online June 28. 10.1111/j.1468-3083.2012.04619.
18. Rhodes LE, de Rie MA, Leifsdottir R, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol 2007, 143:1131-1136.
19. Blackwelder WC " Proving the null hypothesis" in clinical trials. Control Clin Trials 1982, 3:345-353.
20. Rosner B Fundamentals of biostatistics 2011, Brooks/Cole, Cengage Learning, Boston. 7th edn.
21. Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and non-randomized trials. Br J Dermatol 2012, 167:733-756.
22. Basset-Seguin N, Ibbotson SH, Emtestam L, et al. Topical methyl aminolaevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol 2008, 18:547-553.
23. Szeimies RM, Ibbotson S, Murrell DF, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol 2008, 22:1302-1311.
24. Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol 2008, 18:677-682.
25. Quirk C, Gebauer K, De'Ambrosis B, Slade HB, Meng TC Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis 2010, 85:318-324.
26. Ruiz-Villaverde R, Sanchez-Cano D, Burkhardt-Perez P Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week period: a case series. J Eur Acad Dermatol Venereol 2009, 23:828-831.
27. Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000, 71:724-729.
28. Vun Y, Siller G Use of 5% imiquimod cream in the treatment of facial basal cell carcinoma: a 3-year retrospective follow-up study. Australas J Dermatol 2006, 47:169-171.